Inactive Instrument

Highlights Heat Biologics Inc Nasdaq

Equities

US42237K1025

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Scorpius Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 26	CI
Scorpius Holdings Gets Non-Compliance Notice From NYSE American	Apr. 23	MT
North American Morning Briefing : Stock Futures -2-	Apr. 11	DJ
Scorpius Holdings, Inc. Wins Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University	Mar. 19	CI
Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023	Mar. 07	CI
NightHawk?s Scorpius BioManufacturing Subsidiary Receives Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program	Jan. 25	CI
Nighthawk?S Scorpius Biomanufacturing Subsidiary Commences Work on Preclinical Program for New Client	Jan. 16	CI
Scorpius BioManufacturing Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement for A Leading National University	Jan. 03	CI
Jeffrey Wolf acquired Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc..	Dec. 26	CI
NightHawk Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Jeffrey Wolf submitted a preliminary, non-binding offer letter to acquire Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. for $40.5 million.	23-08-20	CI
NightHawk Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
NightHawk Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
NightHawk Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
NightHawk Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Nighthawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory	22-08-23	CI
NightHawk Biosciences, Inc. Executes Research and Development License Agreement with Lytic Solutions, LLC	22-08-22	CI
NightHawk Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-10	CI
NightHawk Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Heat Biologics Unit Plans New Biomanufacturing Facility in Kansas	22-04-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Heat Biologics Inc Nasdaq

Equities

US42237K1025

Highlights

Filters